On The Pen puts compounded and brand-name GLP-1 drugs side by side and checks how well people actually understand the difference between the two.
Recap by typeshit. Full story at On The Pen™ GLP-1 News.
Fiscal.ai posted a chart comparing Lilly and Novo Nordisk and says Lilly is pulling ahead in the obesity drug market. Only the chart is shared, with no other detail.
A short clip of Rosie O'Donnell discussing the tirzepatide drug Mounjaro. Few details are given beyond the title.
Sam Stone mixed GLP-1 Daily Support powder into a smoothie daily and came away with stomach aches and doubts about what it does.
Dr Desmond Wai shares the Novo Nordisk news and notes the FDA cleared semaglutide for fatty liver disease in the US more than a year earlier.
A short personal check-in from a creator who tags her post with tirzepatide. No numbers or details beyond the update itself.
Zhavoronkov points to an analysis across major semaglutide trials and says the later effects on organ aging are only partly explained by weight loss.
Loading…